EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cancer immunotherapy by γδ T cells

Adrian Hayday iD, Julie Dechanet-Merville iD, Jamie Rossjohn iD, Bruno Silva-Santos iD

Science · 04.10.2024 · 386 (6717)

DOI: 10.1126/science.abq7248 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science, erschienen am 04.10.2024. Verfasst von Adrian Hayday und 3 weiteren Autor:innen. Beteiligte Einrichtung: Francis Crick Institute, London, UK. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Intraepithelial Lymphocytes, Neoplasms, Receptors, Antigen, T-Cell, gamma-delta. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The premise of cancer immunotherapy is that cancers are specifically visible to an immune system tolerized to healthy self. The promise of cancer immunotherapy is that immune effector mechanisms and immunological memory can jointly eradicate cancers and inoperable metastases and de facto vaccinate against recurrence. For some patients with hitherto incurable diseases, including metastatic melanoma, this promise is being realized by game-changing immunotherapies based on αβ T cells. Today’s challenges are to bring benefit to greater numbers of patients of diverse ethnicities, target more cancer types, and achieve a cure while incurring fewer adverse events. In meeting those challenges, specific benefits may be offered by γδ T cells, which compose a second T cell lineage with distinct recognition capabilities and functional traits that bridge innate and adaptive immunity. γδ T cell–based clinical trials, including off-the-shelf adoptive cell therapy and agonist antibodies, are yielding promising results, although identifiable problems remain. In addressing those problems, we advocate that immunotherapies be guided by the distinctive biology of γδ T cells, as elucidated by ongoing research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveIntraepithelial LymphocytesNeoplasmsReceptors, Antigen, T-Cell, gamma-deltaAnimalsHumansClinical Trials as TopicMelanoma

Substanzen

Receptors, Antigen, T-Cell, gamma-delta

Autor:innen und Institutionen

  • Francis Crick Institute, London, UK.
  • Peter Gorer Department of Immunobiology, King's College London, London, UK.
  • CRUK City of London Cancer Centre, London, UK.
  • ImmunoConcEpT, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5164, University of Bordeaux, Bordeaux, France.
  • Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
  • Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

ORCID-Profile: Adrian Hayday, Julie Dechanet-Merville, Jamie Rossjohn, Bruno Silva-Santos

Förderung

  • Wellcome Trust

Zitieren

APA

Hayday, A., Dechanet-Merville, J., Rossjohn, J., & Silva-Santos, B. (2024). Cancer immunotherapy by γδ T cells. Science, 386(6717). https://doi.org/10.1126/science.abq7248

Vancouver

Hayday A, Dechanet-Merville J, Rossjohn J, Silva-Santos B. Cancer immunotherapy by γδ T cells. Science. 2024;386(6717). doi:10.1126/science.abq7248

BibTeX
@article{Hayday2024,
  author = {Hayday, Adrian and Dechanet-Merville, Julie and Rossjohn, Jamie and Silva-Santos, Bruno},
  title = {Cancer immunotherapy by γδ T cells},
  journal = {Science},
  year = {2024},
  volume = {386},
  number = {6717},
  doi = {10.1126/science.abq7248}
}
Kostenlos starten →